Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin

A.M. Sorrell, J.H. Shand, E. Tonner, M. Gamberoni, P.A. Accorsi, J. Beattie, G.J. Allan, D.J. Flint

Research output: Contribution to journal › Article

26 Citations (Scopus)

Abstract

Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP- and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation.
LanguageEnglish
Pages10883-10889
Number of pages6
JournalJournal of Biological Chemistry
Volume281
Issue number16
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Insulin-Like Growth Factor Binding Protein 5
Plasminogen
Plasminogen Activator Inhibitor 1
Tissue Plasminogen Activator
Insulin-Like Growth Factor I
Heparin
Fibrinolysin
Cell death
Plasminogen Activators
Urokinase-Type Plasminogen Activator
Cell Death
Focal Adhesions
Adhesion
Molecular interactions
Cell-Free System
Biosensing Techniques
Human Mammary Glands
Biosensors

Keywords

  • factor (IGF)-binding protein-5
  • fibrin dependent enhancemt
  • mammary-gland
  • IGF-I
  • hormonal control
  • mediated stimulation
  • amidolytic activity
  • terminal domains
  • epithelial cells
  • amino acids

Cite this

Sorrell, A.M. ; Shand, J.H. ; Tonner, E. ; Gamberoni, M. ; Accorsi, P.A. ; Beattie, J. ; Allan, G.J. ; Flint, D.J. / Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin. In: Journal of Biological Chemistry. 2006 ; Vol. 281, No. 16. pp. 10883-10889.
@article{b2ef57ce20fb4c4bb7b4c4c97e075da9,
title = "Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin",
abstract = "Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP- and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation.",
keywords = "factor (IGF)-binding protein-5, fibrin dependent enhancemt, mammary-gland, IGF-I, hormonal control, mediated stimulation, amidolytic activity, terminal domains, epithelial cells, amino acids",
author = "A.M. Sorrell and J.H. Shand and E. Tonner and M. Gamberoni and P.A. Accorsi and J. Beattie and G.J. Allan and D.J. Flint",
year = "2006",
month = "4",
doi = "10.1074/jbc.M508505200",
language = "English",
volume = "281",
pages = "10883--10889",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
number = "16",

}

Sorrell, AM, Shand, JH, Tonner, E, Gamberoni, M, Accorsi, PA, Beattie, J, Allan, GJ & Flint, DJ 2006, 'Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin' Journal of Biological Chemistry, vol. 281, no. 16, pp. 10883-10889. https://doi.org/10.1074/jbc.M508505200

Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin. / Sorrell, A.M.; Shand, J.H.; Tonner, E.; Gamberoni, M.; Accorsi, P.A.; Beattie, J.; Allan, G.J.; Flint, D.J.

In: Journal of Biological Chemistry, Vol. 281, No. 16, 04.2006, p. 10883-10889.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin

AU - Sorrell, A.M.

AU - Shand, J.H.

AU - Tonner, E.

AU - Gamberoni, M.

AU - Accorsi, P.A.

AU - Beattie, J.

AU - Allan, G.J.

AU - Flint, D.J.

PY - 2006/4

Y1 - 2006/4

N2 - Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP- and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation.

AB - Transgenic mice expressing IGFBP-5 in the mammary gland exhibit increased cell death and plasmin generation. Because IGFBP-5 has been reported to bind to plasminogen activator inhibitor-1 (PAI-1), we determined the effects of this interaction in HC11 cells. PAI-1 prevented plasmin generation from plasminogen and inhibited cleavage of focal adhesions, expression of caspase 3, and cell death. IGFBP-5 could in turn prevent the effects of PAI-1. IGFBP-5 mutants with reduced affinity for IGF-I (N-term) or deficient in heparin binding (HEP- and C-term E and F) were also effective. This was surprising because IGFBP-5 reportedly interacts with PAI-1 via its heparin-binding domain. Biosensor analysis confirmed that, although wild-type IGFBP-5 and N-term both bound to PAI-1, the C-term E had greatly decreased interaction with PAI-1. This suggests that IGFBP-5 does not antagonize the actions of PAI-1 by a direct molecular interaction. In a cell-free system, using tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA) to activate plasminogen, PAI-1 inhibited plasmin generation induced by both activators, whereas IGFBP-5 prevented the effects of PAI-1 on tPA but not uPA. Furthermore, we noted that IGFBP-5 activated plasminogen to a greater extent than could be explained solely by inhibition of PAI-1, suggesting that IGFBP-5 could directly activate tPA. Indeed, IGFBP-5 and the C-term E and F were all able to enhance the activity of tPA but not uPA. These data demonstrate that IGFBP-5 can enhance the activity of tPA and that this can result in cell death induced by cleavage of focal adhesions. Thus IGFBP-5 can induce cell death by both sequestering IGF-I and enhancing plasmin generation.

KW - factor (IGF)-binding protein-5

KW - fibrin dependent enhancemt

KW - mammary-gland

KW - IGF-I

KW - hormonal control

KW - mediated stimulation

KW - amidolytic activity

KW - terminal domains

KW - epithelial cells

KW - amino acids

UR - http://www.jbc.org/cgi/reprint/281/16/10883

UR - http://dx.doi.org/10.1074/jbc.M508505200

U2 - 10.1074/jbc.M508505200

DO - 10.1074/jbc.M508505200

M3 - Article

VL - 281

SP - 10883

EP - 10889

JO - Journal of Biological Chemistry

T2 - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 16

ER -

Sorrell AM, Shand JH, Tonner E, Gamberoni M, Accorsi PA, Beattie J et al. Insulin-like growth factor-binding protein-5 activates plasminogen by interaction with tissue plasminogen activator, independently of its ability to bind to plasminogen activator inhibitor-1, insulin-like growth factor-I, or heparin. Journal of Biological Chemistry. 2006 Apr;281(16):10883-10889. https://doi.org/10.1074/jbc.M508505200

Access to Document